KLTO 202
Alternative Names: AAVmyo.desmin.s-KL; KLTO-202Latest Information Update: 20 Mar 2025
At a glance
- Originator Klotho Neurosciences
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Multiple sclerosis; Neuromuscular disorders
Most Recent Events
- 12 Mar 2025 Klotho Neurosciences plans to initiate a clinical trial in the fourth quarter of 2025
- 27 Feb 2025 Early research in Amyotrophic lateral sclerosis in USA (Parenteral) prior to February 2025 (Klotho Neurosciences pipeline, February 2025)
- 27 Feb 2025 Early research in Multiple sclerosis in USA (Parenteral), prior to February 2025 (Klotho Neurosciences pipeline, February 2025)